Transcenta Holding Limited (HKG:6628)

Market Cap	1.15B +51.0%
Revenue (ttm)	10.31M -57.9%
Net Income	-291.87M
EPS	-0.72
Shares Out	449.89M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,523,500
Average Volume	997,640
Open	2.140
Previous Close	2.160
Day's Range	2.140 - 2.560
52-Week Range	0.990 - 5.800
Beta	-0.18
RSI	58.83
Earnings Date	Mar 30, 2026

About Transcenta Holding

Transcenta Holding Limited, a clinical stage biopharmaceutical company, engages in the discovery, research, development, manufacture, and commercialization of various drugs for unmet medical needs in the People’s Republic of China and the United States. The company develops MSB2311, a humanized PD-L1 monoclonal antibody (mAb) candidate for TMB-H solid tumors; TST001, a humanized claudin 18.2 mAb candidate for solid tumors, such as gastric and gastroesophageal cancer; TST808, a humanized antibody regulating B/plasma cell; TST005, a PD-L1/TGF-β b...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2010
• Employees: 171
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 6628

Financial Performance

In 2024, Transcenta Holding's revenue was 11.26 million, a decrease of -79.09% compared to the previous year's 53.85 million. Losses were -290.29 million, -37.24% less than in 2023.

Financial numbers in CNY